Findings support mitapivat as the first oral disease-modifying therapy for adults with transfusion-dependent α-thalassaemia or β-thalassaemia, providing a new treatment option to reduce transfusion burden in this patient population.
M. Cappellini, Sujit Sheth, A. Taher et al.· The Lancet· 3 citations
The emerging role of repurposed low-cost therapies, particularly hydroxyurea and thalidomide, as disease-modifying options in resource-limited settings are discussed and opportunities to democratise access to curative gene therapies through technological developments, decentralised manufacturing, regional collaboration...
Hanny T. Al-Samkari, F. Aboobacker, B. Andemariam et al.· The Lancet Haematology· 2 citations
Human genetic studies have identified key regulators of fetal haemoglobin (HbF) expression, including BCL11A, resulting in therapeutic advances1-8. Yet the mechanisms by which HbF expression is activated remain incompletely understood9. Here we conduct a large multi-ancestry genome-wide association study of HbF levels...
Chun-Jie Guo, U. Arora, Xiao-Heng Cheng et al.· Nature· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.